Get the Stockscreener App
65.60
3.47%
-2.36
After Hours:
65.60
Arcellx Inc stock is traded at $65.60, with a volume of 843.54K.
It is down -3.47% in the last 24 hours and up +1.20% over the past month.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
See More
Previous Close:
$67.96
Open:
$65.63
24h Volume:
843.54K
Relative Volume:
1.40
Market Cap:
$3.57B
Revenue:
$155.82M
Net Income/Loss:
$-40.42M
P/E Ratio:
-92.39
EPS:
-0.71
Net Cash Flow:
$3.58M
1W Performance:
-9.49%
1M Performance:
+1.20%
6M Performance:
-21.45%
1Y Performance:
-5.68%
1-Day Range:
$61.17
$66.37
1-Week Range:
$61.17
$72.43
52-Week Range:
$47.88
$107.37
Arcellx Inc Stock (ACLX) Company Profile
Name
Arcellx Inc
Sector
Industry
Phone
240-327-0603
Address
800 BRIDGE PARKWAY, REDWOOD CITY
Compare ACLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
65.60 | 3.57B | 155.82M | -40.42M | 3.58M | -0.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-24 | Initiated | Redburn Atlantic | Buy |
| Sep-03-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Mar-07-24 | Initiated | Morgan Stanley | Overweight |
| Jan-04-24 | Reiterated | Needham | Buy |
| Dec-19-23 | Initiated | Scotiabank | Sector Outperform |
| Oct-30-23 | Initiated | TD Cowen | Outperform |
| Oct-17-23 | Initiated | UBS | Buy |
| May-18-23 | Initiated | Truist | Buy |
| Apr-14-23 | Initiated | Robert W. Baird | Outperform |
| Mar-14-23 | Initiated | Stifel | Buy |
| Feb-13-23 | Initiated | H.C. Wainwright | Buy |
| Dec-13-22 | Resumed | BofA Securities | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-27-22 | Initiated | Needham | Buy |
| Jul-20-22 | Initiated | Canaccord Genuity | Buy |
| Mar-01-22 | Initiated | BofA Securities | Buy |
| Mar-01-22 | Initiated | SVB Leerink | Outperform |
View All
Arcellx Inc Stock (ACLX) Latest News
Teacher Retirement System of Texas Purchases 1,505 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
In 2025, Will Arcellx Inc (NASDAQ: ACLX) Be Bullish Or Bearish? - Stocks Register
How To Trade (ACLX) - news.stocktradersdaily.com
Swiss National Bank Buys 500 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Raymond James Financial Inc. Acquires New Position in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors - BioSpace
Arcellx Inc Announces Board Changes for Strategic Growth - TipRanks
Arcellx names new board members, gears up for 2026 launch By Investing.com - Investing.com Australia
Arcellx Appoints Andrew Galligan And Kristin Myers To Its Board Of Directors -March 20, 2025 at 04:42 pm EDT - MarketScreener
Arcellx names new board members, gears up for 2026 launch - Investing.com
Arcellx director Kavita Patel sells $107,460 in common stock By Investing.com - Investing.com Australia
Arcellx director Kavita Patel sells $107,460 in common stock - Investing.com India
Arcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness Month - The Manila Times
Charles Schwab Investment Management Inc. Buys 14,992 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx Impressive Safety Data Leaves Doubts (NASDAQ:ACLX) - Seeking Alpha
Bank of New York Mellon Corp Buys 27,350 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
US Bancorp DE Has $462,000 Holdings in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
ACLX June 20th Options Begin Trading - Nasdaq
Arcellx (NASDAQ:ACLX) Shares Gap Up – Time to Buy? - Defense World
Principal Financial Group Inc. Trims Stock Holdings in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Myesha Lacy - IR Impact
CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain - GlobeNewswire Inc.
Need To Know: Analysts Just Made A Substantial Cut To Their Arcellx, Inc. (NASDAQ:ACLX) Estimates - Simply Wall St
We're Not Worried About Arcellx's (NASDAQ:ACLX) Cash Burn - Yahoo Finance
New York State Common Retirement Fund Has $1.55 Million Stock Holdings in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
HC Wainwright Predicts Arcellx’s Q1 Earnings (NASDAQ:ACLX) - Defense World
Optimistic Buy Rating for Arcellx Inc: Promising CAR-T Therapy and Strong Financial Position Highlighted - TipRanks
Arcellx Reports Promising 2024 Financial and Clinical Progress - MSN
Arcellx (NASDAQ:ACLX) Posts Earnings Results, Misses Estimates By $0.24 EPS - MarketBeat
Kavita Patel Sells 1,500 Shares of Arcellx, Inc. (NASDAQ:ACLX) Stock - MarketBeat
State of New Jersey Common Pension Fund D Purchases New Stake in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Arcellx, Inc. (ACLX) Reports Q4 Loss, Lags Revenue Estimates - MSN
Why Arcellx Inc Stocks Are on the Rise - TipRanks
Arcellx Inc’s Anito-cel: Anticipated Market Leader with Strong Efficacy, Safety, and Financial Position - TipRanks
Arcellx Inc: Buy Rating Affirmed on Promising Anito-cel Therapy and Strong Financial Position - TipRanks
Arcellx Inc’s Anito-cel Therapy: Promising Clinical Results and Strategic Partnerships Support Buy Rating - TipRanks
Arcellx Inc’s Anito-cel: Promising Performance and Positive Outlook with Buy Rating - TipRanks
Arcellx, Inc. (NASDAQ:ACLX) Shares Bought by Rhumbline Advisers - Defense World
Rami Elghandour Sells 38,300 Shares of Arcellx, Inc. (NASDAQ:ACLX) Stock - MarketBeat
Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights - BioSpace
Arcellx earnings missed by $0.31, revenue fell short of estimates - Investing.com UK
Arcellx reports FY24 EPS ($2.00), consensus ($1.50) - TipRanks
Arcellx CEO Rami Elghandour sells $2.38 million in stock By Investing.com - Investing.com South Africa
Arcellx CEO Rami Elghandour sells $2.38 million in stock - Investing.com
Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference - BioSpace
State of New Jersey Common Pension Fund D Buys Shares of 23,966 Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx Inc Stock (ACLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):